Search

CMSC Abstracts View

Search Accepted Abstracts
Sending

Search Results

Year ID Type Category Title Authors
2019 SEL01 Poster Self-care

Preliminary Examination of Smartphone-Based Fall Risk Assessment in Individuals with Multiple Sclerosis

Mikaela L Frechette, BS, Katherine L Hsieh, BS and Jacob J Sosnoff, PhD, Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL

2019 SXM01 Poster Symptom Management

Impact of a 12-Week Exercise Intervention on Symptoms of Fatigue, Depressed Mood, and Perceived and Objective Cognitive Impairment in Multiple Sclerosis

Chantel D Mayo, M.Sc., Colleen Lacey, B.Sc. and Jodie R Gawryluk, Ph.D. R.Psych., Psychology, University of Victoria, Victoria, BC, Canada

2019 SXM02 Poster Symptom Management

The Effect of Telephone-Based Physical Activity Counseling on Fatigue Impact in MS

Charles H Bombardier, PhD, Rehabilitation Medicine, University of Washington, Seattle, WA, Anna E Evans, MA, BS, Department of Rehabilitation Medicine, University of Washington, Seattle, WA and George H Kraft, MD, MS, Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, WA

2019 SXM03 Poster Symptom Management

Complications of Intrathecal Baclofen Therapy in MS Patients with Severe Spasticity Based on Ambulation Status

Jennifer Hartman, MPAS, PA-C1, Justin Abbatemarco, MD2, Austin C Griffin, BA3, Andre Machado, M.D., Ph.D.4, Keith McKee, MD5, Sean Nagel, MD6 and Francois Bethoux, MD5, (1)Neurological Institute, Cleveland Clinic Mellen Center, Cleveland, OH, (2)Neurological Institute, Cleveland Clinic, Cleveland, OH, (3)Case Western Reserve University School of Medicine, Cleveland, OH, (4)Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, (5)Department of Rehabilitation Services, Cleveland Clinic Mellen Center, Cleveland, OH, (6)Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH

2019 SXM04 Poster Symptom Management

Cannabis and Multiple Sclerosis: A Systematic Review Examining Utilization and Effectiveness

Natasha Breward, MSc (c)1, Nafisa Absher, MSc2, Katherine Knox, MD2, Jane Alcorn, PhD1 and Charity Evans, PhD1, (1)College of Pharmacy & Nutrition, University of Saskatchewan, Saskatoon, SK, Canada, (2)College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada

2019 SXM05 Poster Symptom Management

Assessing Long-Term Performance in Physical Therapy of Multiple Sclerosis Patients Using Dalfampridine

Elhaam Iranmanesh, BS, Kristen Zemina, MD, Carrie Downey, DO, Angela Aungst, MPH, Lise Casady, MSCN, ARNP-C, Chetan P Gandhy, MD, Janice Maldonado, MD and Derrick Robertson, MD, College of Medicine, Neurology, University of South Florida, Tampa, FL

2019 SXM06 Poster Symptom Management

Assessing the Prevalence and Impact of Sleep-Related Disorders on Fatigue in Those with Multiple Sclerosis

Carrie Downey, DO, Austin White, BA, Angela Aungst, MPH, Lise Casady, MSCN, ARNP-C, Janice Maldonado, MD and Derrick Robertson, MD, College of Medicine, Neurology, University of South Florida, Tampa, FL

2019 SXM07 Poster Symptom Management

Arbaclofen Extended Release Tablets Vs Placebo or Baclofen for the Treatment of Spasticity in Subjects with Multiple Sclerosis (Study OS440-3002)

Daniel Kantor, MD, FAAN, FANA1, Tina deVries, PhD2, Angela Dentiste, MBA2 and David Jacobs, MD, MBA2, (1)Florida Atlantic University, Boca Raton, FL, (2)Osmotica Pharmaceuticals, Bridgewater, NJ

2019 SXM08 Poster Symptom Management

One-Year Study to Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets in Multiple Sclerosis-Related Spasticity (Study OS440-3003)

Samuel F. Hunter, MD, PhD1, Tina deVries, PhD2, Angela Dentiste, MBA2 and David Jacobs, MD, MBA2, (1)Advanced Neurosciences Institute, Franklin, TN, (2)Osmotica Pharmaceuticals, Bridgewater, NJ

2019 SXM09 Poster Symptom Management

Step-Wise Approach for Treating Intention Tremor (SWAT-IT2) Community Application

Daniel Engel, BA Psychology; Occupational Therapy Student, Occupational Science and Occupational Therapy, University of British Columbia, Vancouver, BC, Canada

2018 CG01 Platform/Oral Cognition/Psychosocial

Impact of a Cognitive Rehabilitation Intervention on Depressive Symptoms

Alexa Stuifbergen, RN, PhD, FAAN1, Heather Becker, PhD, Research Scientist1 and Francisco Perez, PhD2, (1)School of Nursing, The University of Texas at Austin, Austin, TX, (2)University of Texas at Austin, Austin, TX

2018 CG02 Platform/Oral Cognition/Psychosocial

Imaging Cognitive Fatigue in Multiple Sclerosis: A Preliminary Quantification of Global Cerebral Blood Flow Using ASL Perfusion fMRI

Jason A Berard, B.Sc.H.1,2, Lisa A.S. Walker, Ph.D.1,2,3,4 and Andra M Smith, Ph.D.1,2,4, (1)Psychology, University of Ottawa, Ottawa, ON, Canada, (2)The Ottawa Hospital Research Institute, Ottawa, ON, Canada, (3)Psychology, The Ottawa Hospital, Ottawa, ON, Canada, (4)University of Ottawa Brain and Mind Research Institute, Ottawa, ON, Canada

2018 CG03 Platform/Oral Cognition/Psychosocial

Cognitive Behavioral Therapy for Insomnia to Address Insomnia Symptoms in Individuals with Multiple Sclerosis

Catherine Siengsukon, PT, PhD1, Mohammed Alshehri, PT, MS1, Michelle Drerup, Psy.D., C.BSM2 and Sharon G Lynch, MD3, (1)Physical Therapy and Rehabilitation Science, University of Kansas Medical Center, Kansas City, KS, (2)Sleep Disorders Center, Cleveland Clinic, Cleveland, OH, (3)Neurology, University of Kansas Medical Center, Kansas City, KS

2018 CG04 Platform/Oral Cognition/Psychosocial

Effects of Dual Tasking on the Neural Control System Underlying Mobility in Adults with Multiple Sclerosis

Susan Kasser, Ph.D.1, Kaley Ahern, BS1, Tyler Triquet, BS1, Kyle Hinsdale, BS1 and Ryan S McGinnis, Ph.D.2, (1)Rehabilitation and Movement Science, University of Vermont, Burlington, VT, (2)Electrical and Biomedical Engineering, University of Vermont, Burlington, VT

2018 CG05 Platform/Oral Cognition/Psychosocial

Short-and Long-Term Impact of Mindfulness-Based Stress Reduction for People with MS: A Randomized Clinical Trial

Angela Senders, ND, MCR1,2, Douglas Hanes, PhD2, Dennis Bourdette, MD1, Lynn Marshall, Sc.D.3,4 and Lynne Shinto, ND, MPH1, (1)Neurology, Oregon Health & Science University, Portland, OR, (2)Helfgott Research Institute, National University of National Medicine, Portland, OR, (3)Orthopedics and Rehabilitation, Oregon Health & Science University, Portland, OR, (4)OHSU-PSU School of Public Health, Portland, OR

2018 CG06 Platform/Oral Cognition/Psychosocial

Physical and Mental Health Outcomes Following Unemployment: A Preliminary Report

Lauren B Strober, Ph.D., Neuropsychology & Neuroscience Research, Kessler Foundation, West Orange, NJ

2018 DA01 Platform/Oral Disease Assessment and Management

Clinical Cannabis Interprofessional Education: Program Development and Provider Knowledge

Kim D Jones, PhD, Nursing, Oregon Health & Science University, Portland, OR, Joseph S. Bubalo, Pharm D, Pharmacy, Oregon Health & Science University, Portland, OR, Colin M. Roberts, MD, Neurology, Oregon Health & Science University, Portland, OR and Michelle H Cameron, MD, PT, Neurology, VA Portland Health Care System, Portland, OR; Neurology, Oregon Health and Science University, Portland, OR

2018 DA02 Platform/Oral Disease Assessment and Management

Optimal Inter-Eye Difference Thresholds in Retinal Nerve Fiber Layer and Ganglion Cell Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis

2018 DA03 Platform/Oral Disease Assessment and Management

Rationale and Design of the Traditional Versus Early Aggressive Therapy for MS (TREAT-MS) Trial

Scott D. Newsome, DO1, Thomas J Shoemaker, MD1, Sandra D Cassard, ScD1, Elizabeth Ogburn, PhD2, Jerry Prince, PhD3 and Ellen M Mowry, MD, MCR4, (1)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (2)Johns Hopkins School of Public Health, Baltimore, MD, (3)Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, (4)Neurology, Johns Hopkins School of Medicine, Baltimore, MD

2018 DA04 Platform/Oral Disease Assessment and Management

Derivation and Validation of a Predictive Model for 30-Day Readmission Risk in Patients with Multiple Sclerosis

Kanika Sharma, MD1, Yubo Gao, PhD2, Junlin Liao, PhD3, John A Kamholz, MD, PhD1, Frank R Bittner, MD1 and Piyush Kalakoti, MD4, (1)Neurology, University of Iowa, Iowa City, IA, (2)Medicine, University of Iowa, Iowa City, IA, (3)Surgery, University of Iowa, Iowa City, IA, (4)University of Iowa, Iowa City, IA

2018 DA05 Platform/Oral Disease Assessment and Management

Myelin Signal Isolated MRI (siMRI): A Novel Technique to Quantify Myelin Integrity Reveals Loss of Brain Architectonics in Multiple Sclerosis

Tatiana Wolfe, PhD1, Caio C Quini, PhD2, Philip J Horner, PhD2 and Ruchika S. Prakash, PhD1, (1)Department of Psychology, The Ohio State University, Columbus, OH, (2)Neuroregeneration – Regenerative Medicine, Houston Methodist Research Institute, Houston, TX

2018 DA06 Platform/Oral Disease Assessment and Management

The North American Registry for Care and Research in Multiple Sclerosis

Kottil Rammohan, MD1, Anne Cross, MD2, David Jones, MD3, June Halper, MSN, ANP, FAAN4, Sara McCurdy Murphy, BA5, Lisa Patton, BA5, Edward J. Fox, MD, PhD6, Lori Mayer, DNP, MSN, RN, MSCN7 and Michael K Racke, MD8, (1)University of Miami, Miami, FL, (2)Washington University in St. Louis, St. Louis, MO, (3)UVA, Charlottesville, VA, (4)CEO-CMSC, Hackensack, NJ, (5)CRB, Social & Scientific Systems, Inc., Silver Spring, MD, (6)Central Texas Neurology Consultants, Round Rock, TX, (7)Central Texas Neurology Consultants,, Round Rock, TX, (8)Wexner Medical Center, Ohio State University, Columbus, OH

2018 DA07 Platform/Oral Disease Assessment and Management

Obesity at Onset Impacts the Early Clinical Presentation of Multiple Sclerosis

Farren B.S. Briggs, Ph.D. Sc.M.1, Justin Yu, MS(c) BS1, Jinghong Jiangyang, MS(c) B.S.1, Erica Utigard, DO2, Douglas D. Gunzler, Ph.D.1 and Daniel Ontaneda, MD3, (1)Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, (2)Department of Neurology, The Cleveland Clinic, Cleveland, OH, (3)Cleveland Clinic, Cleveland, OH

2018 DA08 Platform/Oral Disease Assessment and Management

Pediatric-Onset Multiple Sclerosis Is Associated with Reduced Parental Health-Related Quality of Life and Family Functioning

Julia O’Mahony, BSc1, Ruth Ann Marrie, MD, PhD2, Amit Bar-Or, MD3, E Ann Yeh, MD1 and Brenda Banwell, MD4, (1)Hospital for Sick Children, Toronto, ON, Canada, (2)University of Manitoba, Winnipeg, MB, Canada, (3)University of Pennsylvania, Philadelphia, PA, (4)Children’s Hospital of Philadelphia, Philadelphia, PA

2018 DX64 Platform/Oral Disease Modifying Therapy

Confirmed Disability Improvement in Patients with Relapsing Multiple Sclerosis in the Open-Label Extension Period of the Pooled Opera Trials

2018 DX65 Platform/Oral Disease Modifying Therapy

Durable Improvements in MRI Disease Activity and Brain Volume Loss with Alemtuzumab in RRMS Patients: 7-Year Follow-up of Care-MS II

Daniel Pelletier, MD1, Anthony Traboulsee, MD2, Michael Barnett, PhD, MD3, Giancarlo Comi, MD4, Jerome de Seze, MD PhD5, Alex Rovira, MD6, Sven Schippling, MD7, Luke Chung, MD, MPH8, Nadia Daizadeh, PhD8, Kunio Nakamura, PhD9, Douglas L Arnold, MD10,11 and on behalf of the CARE-MS II, CAMMS03409, and TOPAZ, Investigators12, (1)Keck School of Medicine of University of Southern California, Los Angeles, CA, (2)University of British Columbia, Vancouver, BC, Canada, (3)University of Sydney, Sydney, NSW, Australia, (4)University Vita-Salute San Raffaele, Milan, Italy, (5)University Hospital of Strasbourg, Strasbourg, France, (6)Vall d’Hebron University Hospital, Barcelona, Spain, (7)Neuroimmunology and Multiple Sclerosis Research, University Hospital Zurich and University of Zurich, Zurich, Switzerland, (8)Sanofi, Cambridge, MA, (9)Cleveland Clinic, Cleveland, OH, (10)Montreal Neurological Institute, McGill University, Montreal, QC, Canada, (11)NeuroRx Research, Montreal, QC, Canada, (12)on behalf of the CARE-MS II, CAMMS03409, and TOPAZ Investigators, NJ

2018 DX66 Platform/Oral Disease Modifying Therapy

Active RRMS Patients Show Disability Improvements in Each Functional System Following Treatment with Alemtuzumab: Results from CARE-MS II Extension

Samuel F Hunter, MD1, Rany A Aburashed, DO2, Raed Alroughani, MD3, Steven M Bromley, MD, FAAN4,5, Dominique Dive, MD, PhD6, Guillermo Izquierdo, MD7, Ho Jin Kim, MD8, Jan Lycke, MD9, Richard AL Macdonell, MD10, Carlo Pozzilli, MD11, Basil Sharrack, MD, PhD12, Patrick Vermersch, MD13, Andreas Lysandropoulos, MD, PhD14, Luke Chung, MD, MPH15, Nadia Daizadeh, PhD15, Heinz Wiendl, MD16 and on behalf of the CARE-MS II and CAMMS03409, Investigators17, (1)Advanced Neurosciences Institute, Franklin, TN, (2)Institute for Neurosciences and Multiple Sclerosis, Owosso, MI, (3)Amiri Hospital, Sharq, Kuwait, (4)South Jersey MS Center, Audubon, NJ, (5)Bromley Neurology, PC, Linwood, NJ, (6)University Hospital Centre of Liege, Liege, Belgium, (7)Virgen Macarena University Hospital, Seville, Spain, (8)Research Institute and Hospital of National Cancer Center, Goyang, Korea, Republic of (South), (9)Sahlgrenska University Hospital, Gothenburg, Sweden, (10)Austin Health and Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia, (11)Sapienza University of Rome, Rome, Italy, (12)Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, (13)University of Lille, Lille, France, (14)Sanofi, Naarden, Netherlands, (15)Sanofi, Cambridge, MA, (16)University of Munster, Munster, Germany, (17)on behalf of the CARE-MS II and CAMMS03409 Investigators, NA, NJ

2018 DX67 Platform/Oral Disease Modifying Therapy

Impact of Ocrelizumab on Cognition in Patients at Increased Risk of Developing Progressive Disease

Ralph H Benedict, PhD1, Jerome de Seze, MD, PhD2, Stephen L Hauser, MD3, Ludwig Kappos, MD4, Jerry S Wolinsky, MD5, Hanzhe Zheng, PhD6, Shibeshih Belachew, MD, PhD7, Laura Julian, PhD6, Ashish Pradhan, MD6, Fred Lublin, MD8 and Stanley Cohan, MD, PhD9, (1)Department of Neurology, University at Buffalo, Buffalo, NY, (2)University Hospital of Strasbourg, Strasbourg, France, (3)University of California, San Francisco, San Francisco, CA, (4)University Hospital Basel, University of Basel, Basel, Switzerland, (5)McGovern Medical School, UTHealth, Houston, TX, (6)Genentech, Inc., South San Francisco, CA, (7)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (8)Icahn School of Medicine at Mount Sinai, New York, NY, (9)Providence Multiple Sclerosis Center, Portland, OR

2018 DX68 Platform/Oral Disease Modifying Therapy

Effects of Fingolimod on Magnetic Resonance Imaging Outcomes in Patients with Pediatric-Onset Multiple Sclerosis: Results from the Phase 3 Paradigms Study

Douglas L Arnold, MD1,2, Brenda Banwell, MD3, Amit Bar-Or, MD4,5, Angelo Ghezzi, MD6, Benjamin Greenberg, MD, MHS7, Emmanuelle Waubant, MD, PhD8, Gavin Giovannoni, PhD9, Jerry S Wolinsky, MD10, Jutta Gaertner, MD11, Kevin Rostasy, MD12, Lauren Krupp, MD13, Marc Tardieu, MD14, Wolfgang Brueck, MD15, Tracy Stites, PhD16, Gregory L Pearce, PhD16, Martin Merschhemke, MD, PhD17 and Tanuja Chitnis, MD18, (1)NeuroRx Research, Montreal, QC, Canada, (2)Montreal Neurological Institute, McGill University, Montreal, QC, Canada, (3)Children’s Hospital of Philadelphia, Philadelphia, PA, (4)Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (5)Neuroimmunology Unit, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, (6)Gallarate Hospital, Gallarate, Italy, (7)Neurology & Neurotherapeutics – MS Clinic, UT Southwestern Medical Center, Dallas, TX, (8)UCSF Neurology, Weill Institute for Neurosciences, San Francisco, CA, (9)Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK, London, United Kingdom, (10)McGovern Medical School, UTHealth, Houston, TX, (11)Department of Paediatrics and Adolescent Medicine, German Centre for Multiple Sclerosis in Childhood and Adolescence University Medical Centre, Goettingen, Germany, (12)Division of Paediatric Neurology, Children’s Hospital Datteln, University Witten/Herdecke, Datteln, Germany, (13)Pediatric MS Center, NYU Langone Medical Center, New York, NY, (14)Bicetre Hospital, Paris, France, (15)Department of Neuropathology, University Medical Centre, Goettingen, Germany, (16)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (17)Novartis Pharma AG, Basel, Switzerland, (18)Massachusetts General Hospital, Partners Pediatric MS Center, Boston, MA

2018 DX69 Platform/Oral Disease Modifying Therapy

Efficacy and Safety of Ozanimod Versus Interferon Beta-1a in Two Randomized, Double-Blind, Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B)

2018 DX71 Platform/Oral Disease Modifying Therapy

Phase 2 Multicenter Study Results of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)

Edward J. Fox, MD, PhD1, Amy Lovett-Racke, PhD2, Matilde Inglese, MD, PhD3, Maria Petracca, MD, PhD4, Sibyl Wray, MD5, Michael K Racke, MD6, Richard Shubin, MD7, Cary L Twyman, MD8, Michael Weiss, JD9, James Eubanks, PhD9, Koby Mok, PhD9 and Wendy Su, PhD9, (1)Central Texas Neurology Consultants, Round Rock, TX, (2)Microbial Infection and Immunity, Ohio State University Medical Center, Columbus, OH, (3)Department of Neurology, Radiology and Neuroscience, Mount Sinai School of Medicine, New York, NY, (4)Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, (5)Hope Neurology MS Center, Knoxville, TN, (6)Wexner Medical Center, Ohio State University, Columbus, OH, (7)SC3 Research Group, Inc, Pasadena, CA, (8)Associates in Neurology PSC, Lexington, KY, USA, Lexington, KY, (9)Autoimmune, TG Therapeutics, Inc, New York, NY

2018 RH26 Platform/Oral Rehabilitation

Continuous Remote Assessment of Multiple Sclerosis Disability over One Year: The UCSF Fitrims Study

Valerie A J Block, PT, DPTSc1, Riley Bove, MD, MMSc2, Chao Zhao, MSc3, Priya Garcha, BSc3, Jennifer S Graves, M.D. PhD3, Andrew Romeo, MD3, Ari J Green, MD3, Jill Hollenbach, PhD1, Jeffrey E Olgin, MD4, Gregory M Marcus, MD, MAS, FACC, FAHA, FHRS5, Mark Pletcher, MD, MPH6, Bruce AC Cree, MD, PhD3,7 and Jeffrey M Gelfand, MD, MAS3, (1)Neurology, University of California San Francisco, San Francisco, CA, (2)University of California San Francisco, Weill Institute for Neurosciences, San Francisco, CA, (3)UCSF Neurology, Weill Institute for Neurosciences, San Francisco, CA, (4)Medicine, University of California San Francisco, San Francisco, CA, (5)Cardiology, University of California San Francisco, San Francisco, CA, (6)Epidemiology, University of California San Francisco, San Francisco, CA, (7)Neurology, University of California, San Francisco, CA

2018 RH27 Platform/Oral Rehabilitation

Inpatient Multidisciplinary Rehabilitation: Long-Term Effectiveness on Health-Related Quality of Life in MS Patients. – the Danish MS Hospitals Rehabilitation Study

Michael Norgaard, MSc1, Finn Boesen, MD1, Peter V Rasmussen, Phd2, Thor Petersen, DMSc2, Anders G Skjerbaek, MRSc1, Philipp Trenel, Phd3 and Brita Lovendahl, MSc1, (1)The Danish MS Hospitals, Haslev and Ry, Denmark, (2)Aarhus University Hospital, Aarhus, Denmark, (3)Danish Technological Institute, Aarhus, Denmark

2018 RH28 Platform/Oral Rehabilitation

Usability of the Atomic (Active Teens Multiple Sclerosis) Mobile App to Increase Physical Activity in Pediatric Multiple Sclerosis

Samantha Stephens, PhD1, Stephanie A Grover, MSc, CCRP1, Jennifer Stinson, N-EC, PhD, CPNP, FAAN2,3, Robert W Motl, PhD4, Marcia Finlayson, PhD, OT Reg (Ont), OTR5 and E. Ann Yeh, MD, MA, FRCPC, Dip ABPN6, (1)Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON, Canada, (2)Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, (3)Lawrence S. Bloomberg, Faculty of Nursing,, University of Toronto, Toronto, ON, Canada, (4)Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (5)School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada, (6)Neurology, The Hospital for Sick Children, Toronto, ON, Canada

2018 RH29 Platform/Oral Rehabilitation

Maximal Strength Training in MS: Effects on Mobility Deficits

Herb Karpatkin, PT, DSc, NCS, MSCS1, Michael Zervas, DPT2, Mark Wnukowski, DPT3, Alexandra Cerrati, SPT4, Michelle Shamsian, SPT4, Niki Chan, SPT5 and Kelly Kaems, DPT4, (1)Physical Therapy, Hunter College, New York, NY, (2)Physical therapy, Hunter College, New York, NY, (3)Physical therapy, Hunter CollegeNew York, New York, NY, (4)Hunter College, New York, NY, (5)Hunter College, New york, NY

2018 RH30 Platform/Oral Rehabilitation

Correlation of Patient Report of Speech and Swallowing Difficulty with Diadochokinetic Rate

Lori A Kostich, M.S. CCC-SLP, MSCS, Mount Sinai Rehabilitation Hospital, Hartford, CT

2018 RH31 Platform/Oral Rehabilitation

The Effect of Yoga on Relapsing Remitting Multiple Sclerosis Related Fatigue in Adults

Dr. Patricia M. Rodriguez-Hudson, DNP CRNP RNFA, Family Practice, Coordinated Health, Hazleton, PA; Nursing Dept, Misericordia University, Dallas, PA and Dr. Timothy Kelly, DPT CEAA, PT, St. Luke’s Miners Memorial Hopsital, Coaldale, PA

2018 CA01 Poster Complementary and Alternative Therapies

Project Complete: Promotion of Exercise in Multiple Sclerosis through Healthcare Providers

Emma Richardson, PhD1, Robert W Motl, PhD2, Elizabeth Barstow, PhD3, Sarah Blaylock, PhD2 and Matthew Fifolt, PhD4, (1)Department of Physical Therapy, UAB, Birmingham, AL, (2)Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (3)Department of Occupational Therapy, University of Alabama at Birmingham, Birmingham, AL, (4)Health Care Organization & Policy, University of Alabama at Birmingham, Birmingham, AL

2018 CA02 Poster Complementary and Alternative Therapies

Effect of Vitamin D on Multiple Sclerosis Relapse

Renu Pokharna, MD1, Miles Reese, MD Candidate2 and Souvik Sen, MD, Neurology Chair1, (1)Neurology, University of South Carolina School of Medicine, Columbia, SC, (2)University of South Carolina School of Medicine, Columbia, SC

2018 CA03 Poster Complementary and Alternative Therapies

Exploring Wellness-Based Interventions in People with Multiple Sclerosis: An Evidence-Based Review

Myriam Venasse, BSc1, Thomas A Edwards, MSc2 and Lara A. Pilutti, PhD1, (1)Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON, Canada, (2)School of Human Kinetics, University of Ottawa, Ottawa, ON, Canada